Taxanes: 4 Common Cutaneous Side Effects And Management

Taxanes represent a vital class of chemotherapeutic agents derived originally from the bark of the Pacific yew tree (Taxus brevifolia). These drugs, primarily paclitaxel and docetaxel, have revolutionised oncology by targeting rapidly dividing cancer cells through disruption of microtubule dynamics.

Introduction

Taxanes are antineoplastic medications widely employed in the management of various solid tumours. First isolated in the 1960s, their clinical utility expanded dramatically in the 1990s following the development of semi-synthetic analogues that improved solubility and reduced toxicity associated with natural extraction. Today, paclitaxel (Taxol®) and docetaxel (Taxotere®) remain cornerstones in regimens for breast, ovarian, lung, and other cancers. Nab-paclitaxel, a solvent-free albumin-bound formulation, offers an alternative with potentially altered toxicity profiles.

While highly effective, taxanes are notorious for inducing dermatological adverse events affecting up to 90% of patients. These reactions span hair, nails, mucosa, and skin, often manifesting in a dose-dependent manner. Docetaxel tends to provoke more frequent and severe cutaneous effects compared to paclitaxel.

How they work

Taxanes exert their cytotoxic effects by stabilising microtubules, preventing their depolymerisation during mitosis. This inhibition of spindle apparatus formation arrests cells in the G2/M phase of the cell cycle, triggering apoptosis. Unlike vinca alkaloids, which destabilise microtubules, taxanes promote hyperstabilisation, selectively targeting cells with high proliferative rates such as malignant tumours.

Microtubules comprise α- and β-tubulin heterodimers essential for intracellular transport, cell shape maintenance, and chromosomal segregation. Taxanes bind primarily to β-tubulin, suppressing dynamic instability required for proper mitotic progression. This mechanism underlies both antitumour efficacy and toxicity to rapidly renewing tissues like skin appendages and mucosa.

Clinical uses

Taxanes feature prominently across oncology:

• Breast cancer: Adjuvant therapy for node-positive disease; neoadjuvant for locally advanced tumours; metastatic setting often combined with anthracyclines or trastuzumab.
• Ovarian cancer: First-line with carboplatin; recurrent disease.
• Non-small cell lung cancer (NSCLC): Platinum-based doublets.
• Prostate cancer: Docetaxel standard for metastatic castration-resistant disease.
• Gastric cancer: Second-line therapy.
• Head and neck cancers: Induction or concurrent chemoradiotherapy.

Administration schedules vary: paclitaxel weekly (80 mg/m²) or every 3 weeks (175 mg/m²); docetaxel typically every 3 weeks (75–100 mg/m²). Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) allows higher dosing with cremophor-free delivery.

Adverse effects

Beyond cutaneous reactions, taxanes cause haematological toxicity (neutropenia), neuropathy, myalgia/arthralgia, fatigue, nausea, and hypersensitivity. Premedication with dexamethasone, H1/H2 blockers mitigates infusion reactions linked to cremophor EL solvent in conventional paclitaxel.

Peripheral sensory neuropathy, manifesting as painful paraesthesias in fingers/toes, affects 60–70% of patients and may necessitate dose reduction. Febrile neutropenia risk is higher with docetaxel.

Cutaneous adverse effects

Dermatological toxicities represent the most visible and patient-impacting side effects, occurring in most patients. Reactions are generally reversible upon discontinuation but impact quality of life.

Alopecia

Acute reversible

alopecia

develops universally, typically grades 2–3 (visible scalp hair loss). Anagen effluvium peaks 2–3 weeks post-initiation due to mitotic arrest in hair bulb matrix cells. Scalp cooling (cold caps) significantly reduces incidence (from 96% to 29–50%) by inducing vasoconstriction and reducing drug delivery.

Nail disorders

**Nail toxicity** affects 35–44% of patients, more commonly with docetaxel. Characteristic

onycholysis

(nail plate separation from bed) predominates on toes > fingers. Other manifestations include:

• Beau’s lines (transverse grooves)
• Melanonychia (pigmented bands)
• Leuconychia (white discoloration)
• Onychomadesis (complete nail shedding)
• Paronychia (periungual inflammation)
• Brittle nails, ridging

Pathogenesis involves direct cytotoxicity to keratinising cells, antiangiogenic effects, and possible phototoxicity. Cumulative dose correlates with severity; resolution occurs 2–6 months post-therapy. Prevention strategies include cooling hands/feet during infusion (reducing grade ≥2 events from 22% to 0%) and biotin supplementation, urea-based moisturisers.

Mucositis

**Stomatitis** and

dysgeusia

(taste alteration) occur commonly, especially early in therapy. Oral ulcers, erythema, and metallic taste resolve spontaneously.

Other skin reactions

• Hypersensitivity: Maculopapular rash, urticaria, rarely anaphylaxis (1–3%).
• Folliculitis: Sterile pustules on scalp, shoulders; self-limited.
• Hand-foot syndrome (HFS): Distinct taxane variant with scaly, erythematous, painful lesions on dorsal hands (interphalangeal joints, thenar), feet. Bilateral, prodromal dysaesthesias; biopsy shows fibrosis.
• Recall phenomenon: Exacerbated reactions in previously irradiated fields.
• Sclerodermoid changes: Thickening, fibrosis from cytokine induction (IL-6, TNF-α).
• Xerosis: Dry, scaling skin managed with emollients; barrier disruption elevates transepidermal water loss.
• Pruritus, rash: Morbilliform eruptions.

Psoriasis may paradoxically improve or flare.

Management and prevention

Proactive dermatological support preserves dose intensity:

Reaction	Prevention	Treatment
Alopecia	Scalp cooling	Minoxidil, wigs
Nail toxicity	Cooling gloves/socks, biotin 2.5 mg TID	Urea 40% cream, petroleum, trim nails short
HFS	Cooling, pyridoxine 200 mg BID	Topical steroids, calcipotriol, urea
Xerosis	Daily emollients	Humectants, ceramide creams
Neuropathy	Duloxetine 30–60 mg	Gabapentinoids

Dose adjustments rarely required; early intervention paramount.

Frequently Asked Questions

What are the most common cutaneous side effects of taxanes?

Alopecia, nail dystrophy (onycholysis), hand-foot syndrome, xerosis.

Can scalp cooling prevent taxane-induced hair loss?

Yes, reducing risk by 50–70% in multiple trials.

Do nail changes from taxanes resolve?

Typically within 2–6 months after stopping therapy.

Is docetaxel or paclitaxel worse for skin toxicity?

Docetaxel causes more frequent/severe reactions.

How to manage taxane hand-foot syndrome?

Cooling during infusion, topical corticosteroids, avoid friction.